Literature DB >> 6385896

Comorbid and clinical determinants of prognosis in endometrial cancer.

C K Wells, J K Stoller, A R Feinstein, R I Horwitz.   

Abstract

In cancers of the lung, larynx, rectum, and breast, the patients' initial clinical manifestations and comorbid diseases have shown important prognostic distinctions that are not evident in the customary systems of anatomic staging. This study was done to see whether the same phenomena occurred for cancer of the endometrium. In 142 consecutive cases of endometrial carcinoma, strikingly high five-year survival rates were found in women who had no symptoms attributable to the cancer or whose only symptoms might have been caused either by concomitant uterine or cervical disease or by replacement estrogen therapy. A distinct decline in survival was associated with systemic symptoms and with major comorbid ailments. Estimation of prognosis and evaluation of therapy can be improved with a new composite staging system, formed by combining the new clinical categories and the standard morphologic stages of the International Federation of Gynecology and Obstetrics (FIGO) system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385896

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.

Authors:  Naval Daver; Kiran Naqvi; Elias Jabbour; Tapan Kadia; Courtney DiNardo; Marylou Cardenas-Turanzas; Sherry Pierce; Khanh Thi-Thuy Nguyen; Carlos Bueso-Ramos; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

2.  Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma.

Authors:  Omar A Karadaghy; Dorina Kallogjeri; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

3.  Comparison of Scoring Methods for ACE-27: Simpler Is Better.

Authors:  Dorina Kallogjeri; Jay F Piccirillo; Edward L Spitznagel; Ewout W Steyerberg
Journal:  J Geriatr Oncol       Date:  2012-07-01       Impact factor: 3.599

4.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

Authors:  Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

5.  Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites.

Authors:  M Porta; M Gallén; N Malats; J Planas
Journal:  J Epidemiol Community Health       Date:  1991-09       Impact factor: 3.710

6.  A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.

Authors:  B Colinet; W Jacot; D Bertrand; S Lacombe; M-C Bozonnat; J-P Daurès; J-L Pujol
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

7.  Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.

Authors:  Erica H Lee; Rajiv I Nijhawan; Kishwer S Nehal; Stephen W Dusza; Amanda Levine; Amanda Hill; Christopher A Barker
Journal:  J Skin Cancer       Date:  2015-06-09

8.  Age-adjusted charlson comorbidity index and 30-day morbidity in pelvic surgeries.

Authors:  Sampada B Dessai; R Fasal; J Dipin; D Adarsh; Satheesan Balasubramanian
Journal:  South Asian J Cancer       Date:  2018 Oct-Dec

9.  Comorbidities of idiopathic thrombocytopenic purpura: a population-based study.

Authors:  M A Feudjo-Tepie; G Le Roux; K J Beach; D Bennett; N J Robinson
Journal:  Adv Hematol       Date:  2009-04-02

10.  Impact of comorbidity on outcomes and overall survival after open and minimally invasive esophagectomy for locally advanced esophageal cancer.

Authors:  James P Dolan; Taranjeet Kaur; Brian S Diggs; Renato A Luna; Paul H Schipper; Brandon H Tieu; Brett C Sheppard; John G Hunter
Journal:  Surg Endosc       Date:  2013-07-12       Impact factor: 4.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.